利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.019 秒)

    Compositions containing both sedative and non-sedative antihistamines and sleep aids
    3.
    发明授权
    Compositions containing both sedative and non-sedative antihistamines and sleep aids 有权
    含有镇静和非镇静抗组胺药和睡眠辅助剂的组合物

    公开(公告)号：US07585520B2

    公开(公告)日：2009-09-08

    申请号：US10943311

    申请日：2004-09-17

    申请人： Mark Hirsh ,  Jane Hirsh ,  Whe-Yong Lo

    发明人： Mark Hirsh ,  Jane Hirsh ,  Whe-Yong Lo

    IPC分类号： A61K9/24 ,  A61K9/20 ,  A61K9/22 ,  A61K9/28 ,  A61K9/14

    CPC分类号： A61K45/06 ,  A61K9/209 ,  A61K9/5084 ,  A61K31/00 ,  A61K2300/00

    摘要： Compositions containing both a sedative compound and a non-sedative antihistamine are provided. More particularly, compositions for administration at bedtime containing a sedating antihistamine or other sedating compound in immediate release form and a non-sedating antihistamine in delayed-release form are described. Alternatively, a composition, for administrating upon awakening, containing a non-sedating antihistamine in immediate release form, and a sedating antihistamine or other sedative in delayed-release form is described. Methods of inhibiting the release of histamines by administration of the compositions to a mammalian subject are also provided. The dosage forms may comprise other medications, such as leukotriene receptor antagonists, to enhance the suppression of histamine symptoms.

    摘要翻译： 提供了含有镇静化合物和非镇静抗组胺剂的组合物。 更具体地，描述了在睡前给药的组合物，其含有立即释放形式的镇静抗组胺药或其他镇静化合物和延迟释放形式的非镇静抗组胺药。 或者，描述了用于在觉醒时施用含有立即释放形式的非镇静抗组胺剂的组合物，以及缓释形式的镇静抗组胺药或其他镇静剂。 还提供了通过将哺乳动物受试者施用组合物来抑制组胺释放的方法。 剂型可以包含其他药物，例如白三烯受体拮抗剂，以增强组胺症状的抑制。

    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
    5.
    发明授权
    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent 失效

    公开(公告)号：US06645524B2

    公开(公告)日：2003-11-11

    申请号：US09929838

    申请日：2001-08-14

    申请人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    发明人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    IPC分类号： A61K956

    CPC分类号： A61K9/5084 ,  A61K9/2081 ,  A61K9/209

    摘要： Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a “coated core” dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.

    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
    6.
    发明授权
    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent 失效

    公开(公告)号：US06500457B1

    公开(公告)日：2002-12-31

    申请号：US09639584

    申请日：2000-08-14

    申请人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    发明人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    IPC分类号： A61K920

    CPC分类号： A61K9/5084 ,  A61K9/2081 ,  A61K9/209

    摘要： Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a “coated core” dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.

    Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
    7.
    发明授权
    Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration 失效
    用于口内和口服给药的具有模制的triturate片剂的压缩环形片剂的药物组合物

    公开(公告)号：US07387792B2

    公开(公告)日：2008-06-17

    申请号：US11041474

    申请日：2005-01-24

    申请人： Jane C. Hirsh ,  Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    发明人： Jane C. Hirsh ,  Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    IPC分类号： A61K9/20 ,  A61K9/22 ,  A61K9/24 ,  A61K9/46

    CPC分类号： A61K9/209 ,  A61K9/0056

    摘要： New pharmaceutical compositions in unit dosage form are disclosed for both intraoral and oral administration to a patient, said unit dosage form configured to be placed intraorally of said patient, which comprises: (a) as a first portion, at least one discrete molded triturate tablet comprising a therapeutically effective amount of at least one pharmaceutically active ingredient capable of intraoral administration; and (b) as a second portion located around the said first portion, a therapeutically effective amount of at least one pharmaceutically active ingredient capable of oral administration and which is releasable and orally ingestible by the patient after the molded triturate tablet has disintegrated or has dissolved intraorally.

    摘要翻译： 公开了单位剂量形式的新的药物组合物，用于向患者进行口内和口服给药，所述单位剂型被配置为置于所述患者的口内，其包括：（a）作为第一部分，至少一个离散的模制成型的片剂 包括治疗有效量的至少一种能口内给药的药物活性成分; 和（b）作为位于所述第一部分周围的第二部分，治疗有效量的至少一种能够口服给药的药学活性成分，并且其在模制的特定片剂崩解或溶解之后由患者可释放和口服摄入 口语

    Sprayable formulations for the treatment of acute inflammatory skin conditions
    8.
    发明申请
    Sprayable formulations for the treatment of acute inflammatory skin conditions 审中-公开
    用于治疗急性炎症皮肤病症的可喷雾制剂

    公开(公告)号：US20050255048A1

    公开(公告)日：2005-11-17

    申请号：US11128947

    申请日：2005-05-13

    申请人： Mark Hirsh ,  Jane Hirsh ,  Ira Skolnik ,  Mark Trumbore

    发明人： Mark Hirsh ,  Jane Hirsh ,  Ira Skolnik ,  Mark Trumbore

    IPC分类号： A61K9/12 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/496 ,  A61K31/58 ,  A61K31/65 ,  A61K31/704 ,  A61K31/7048

    CPC分类号： A61K31/58 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/122 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/496 ,  A61K31/65 ,  A61K31/704 ,  A61K31/7048 ,  A61K45/06 ,  A61K2300/00

    摘要： A topical spray or foam, methods of making the formulation, and methods of use thereof, has been developed. In one preferred embodiment, the composition includes one or more active agents and exhibits both antibacterial activity and antifungal activity. Excipients such as chemical disinfectants, anti-pruritic agents to minimize itching, and skin protective compounds may be added. The composition may be formulated to be dispensed as a spray or foam and the spray or foam may be administered either by a hand pump or by an aerosolizing propellant. A second single phase formulation has also been developed. The formulation comprises a first drug which is water soluble or hydrophilic and a second drug which is lipid soluble or hydrophobic, wherein at least one of the drugs is bound to an ion-exchange resin. The use of binding resins, such as ion-exchange resins, allows drugs with incompatible solvent requirements to be prepared in a single-phase formulation.

    摘要翻译： 已经开发了局部喷雾或泡沫，制备方法及其使用方法。 在一个优选的实施方案中，组合物包含一种或多种活性剂并且表现出抗菌活性和抗真菌活性。 可以加入赋形剂如化学消毒剂，抗瘙痒剂以最小化瘙痒和皮肤保护性化合物。 组合物可以配制成以喷雾或泡沫的形式分配，并且喷雾或泡沫可以通过手泵或雾化推进剂施用。 还开发了第二个单相制剂。 该制剂包含水溶性或亲水性的第一药物和脂溶性或疏水性的第二药物，其中至少一种药物与离子交换树脂结合。 使用结合树脂，例如离子交换树脂，可以在单相制剂中制备具有不相容溶剂要求的药物。

    Gelled Periodontal Anesthetic Preparation
    9.
    发明申请
    Gelled Periodontal Anesthetic Preparation 审中-公开
    凝胶牙周麻醉制剂

    公开(公告)号：US20070232695A1

    公开(公告)日：2007-10-04

    申请号：US11534552

    申请日：2006-09-22

    申请人： Mark Hirsh ,  Jane Hirsh ,  Mark Trumbore

    发明人： Mark Hirsh ,  Jane Hirsh ,  Mark Trumbore

    IPC分类号： A61K31/325

    CPC分类号： A61K31/325 ,  A61K9/006 ,  A61K9/0063 ,  A61K31/245 ,  A61K45/06 ,  A61K2300/00

    摘要： A composition for anesthetizing oral or buccal tissues, especially periodontal pockets, is provided. The composition has a high concentration of topical anesthetic carried in a non-aqueous liquid vehicle containing a gelling agent. The anesthetics are optionally stabilized in the solution by ion-exchange complexation. The composition can anesthetize the gingivae for an extended period, such as 30 minutes or longer. Preferred anesthetics include tetracaine, benzocaine, butamben, and mixtures of these.

    摘要翻译： 提供了用于麻醉口腔或颊组织，特别是牙周袋的组合物。 该组合物在含有胶凝剂的非水液体载体中携带高浓度的局部麻醉剂。 麻醉剂任选地通过离子交换络合稳定在溶液中。 组合物可以长时间麻醉牙龈，例如30分钟或更长时间。 优选的麻醉剂包括丁卡因，苯佐卡因，丁苯丁酸及其混合物。

    Non-flammable topical anesthetic liquid aerosols
    10.
    发明申请
    Non-flammable topical anesthetic liquid aerosols 审中-公开
    不易燃的局部麻醉液体气溶胶

    公开(公告)号：US20050123484A1

    公开(公告)日：2005-06-09

    申请号：US10956819

    申请日：2004-10-01

    申请人： Jane Hirsh ,  Donald Tibbetts ,  Mark Hirsh

    发明人： Jane Hirsh ,  Donald Tibbetts ,  Mark Hirsh

    IPC分类号： A61K9/12 ,  A61K31/00 ,  A61K31/24 ,  A61K31/245 ,  A61K45/06 ,  A61P23/02 ,  A61L9/04

    CPC分类号： A61K31/245 ,  A61K9/12 ,  A61K31/00 ,  A61K31/24 ,  A61K45/06 ,  A61K2300/00

    摘要： A topical liquid aerosol formulation for accurate metered dose delivery has been developed which includes a concentrate comprising a local anesthetic in a non-alcohol solvent and a hydrofluorocarbon (HFC) propellant. In the preferred embodiment, the concentration of the non-alcohol solvent in the concentrate is between about 75% and 85% by weight of the formulation. In the most preferred embodiment, the non-alcohol solvent is a water-soluble polyol such as ethylene glycol, propylene glycol, glycerol, diethylene glycol, dipropylene glycol, oligoalkylene glycols, liquid polyalkylene glycols, or combinations thereof. In one embodiment, the concentration of the local anesthetic in the concentrate is between about 15% and 25% by weight. In the preferred embodiment, the hydrofluorocarbon propellant is 1,1,1,2-tetrafluoroethane 1,1,1,2,3,3,3-heptafluoropropane or combinations thereof, in a concentration between about 35% and 65% by weight of the final formulation, more preferably between about 45% and 55% by weight of the final formulation. A particularly preferred formulation includes benzocaine, tetracaine, and butylaminobenzoate, wherein the concentration of benzocaine in the concentrate is 14% by weight, the concentration of tetracaine in the concentrate is 2% by weight, and the concentration of butylaminobenzoate in the concentrate is 2% by weight. It has been found that the formulation is more stable in the substantial absence of oxygen. The formulation is preferably administered using a metered dose device for release of a controlled amount of the local anesthetic.

    摘要翻译： 已经开发了用于精确计量剂量递送的局部液体气溶胶制剂，其包括在非醇溶剂中的局部麻醉剂和氢氟烃（HFC）推进剂的浓缩物。 在优选的实施方案中，浓缩物中非醇溶剂的浓度为制剂重量的约75％至85％。 在最优选的实施方案中，非醇溶剂是水溶性多元醇，例如乙二醇，丙二醇，甘油，二甘醇，二丙二醇，低聚亚烷基二醇，液体聚亚烷基二醇或其组合。 在一个实施方案中，浓缩物中局部麻醉剂的浓度为约15重量％至25重量％。 在优选的实施方案中，氢氟烃推进剂是1,1,1,2-四氟乙烷1,1,1,2,3,3,3-七氟丙烷或其组合，其浓度为约35-65重量％ 最终制剂，更优选为最终制剂重量的约45％至55％。 特别优选的制剂包括苯佐卡因，丁卡因和丁基氨基苯甲酸酯，其中浓缩物中苯佐卡因的浓度为14重量％，浓缩物中丁卡因的浓度为2重量％，浓缩物中丁基氨基苯甲酸酯的浓度为2重量％ 重量。 已经发现，在基本不存在氧的情况下，制剂更加稳定。 制剂优选使用计量剂量装置施用以释放受控量的局部麻醉剂。